Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 8/20 | 0.56 |
| ▸ | MET | P08581 | 12/20 | 0.48 |
| ▸ | AXL | P30530 | 1/20 | 0.48 |
| ▸ | KDR | P35968 | 9/20 | 0.47 |
| ▸ | FLT1 | P17948 | 1/20 | 0.46 |
| ▸ | FLT4 | P35916 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4908570 | 0.95 | MET (0.53) | MAP2K1METAXLKDRFLT1 | |
| SCHEMBL4907892 | 0.93 | MAP2K1 (0.60) | MAP2K1METKDR | |
| SCHEMBL14017378 | 0.87 | MAP2K1 (0.60) | MAP2K1 | |
| SCHEMBL4913711 | 0.81 | MAP2K1 (0.63) | MAP2K1 | |
| SCHEMBL4814828 | 0.79 | MET (0.62) | METAXL | |
| SCHEMBL4907775 | 0.79 | MAP2K1 (0.64) | MAP2K1KDR | |
| SCHEMBL4896473 | 0.78 | MAP2K1 (0.46) | MAP2K1METAXLKDR | |
| SCHEMBL4905542 | 0.76 | MAP2K1 (0.47) | MAP2K1MET | |
| SCHEMBL4904867 | 0.76 | MAP2K1 (0.60) | MAP2K1KDR | |
| SCHEMBL4910453 | 0.76 | MAP2K1 (0.47) | MAP2K1MET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7439246-B2 | Fused heterocyclic kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-10-21 | — | — | US | disclosed |
| US-7439246-B2 | Fused heterocyclic kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-10-21 | — | — | US | disclosed |
| US-7439246-B2 | Fused heterocyclic kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-10-21 | — | — | US | disclosed |
| US-7173031-B2 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-06 | — | — | US | disclosed |
| US-7173031-B2 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-06 | — | — | US | disclosed |
| US-7173031-B2 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-06 | — | — | US | disclosed |
| US-20060211695-A1 | Fused heterocyclic kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2006-09-21 | — | — | US | disclosed |
| US-20060004006-A1 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2006-01-05 | — | — | US | disclosed |
| US-20050288290-A1 | Fused heterocyclic kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288290-A1 | Fused heterocyclic kinase inhibitors | MAP3K20, MAP3K19, ABL1 | MAP2K1 127/4885MET 721/4885AXL 452/4885 |
| US-20060004006-A1 | Pyrrolotriazine kinase inhibitors | MAP3K5, MAP3K15, MAP4K2 | MAP2K1 261/4885MET 2109/4885AXL 880/4885 |
| US-20060211695-A1 | Fused heterocyclic kinase inhibitors | MAP3K20, MAP3K19, ABL1 | MAP2K1 127/4885MET 721/4885AXL 452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.